Table 3.

Percentage of charge variants/ glycans for each biosimilar relative to Humira^® given as a range (average). Each biosimilar is compared to a reference Humira^® (left of biosimilar column) that was tested simultaneously during analysis.

Charge variants/glycans	Humira®	Amgevita™	Humira®	Imraldi™	Humira®	Hyrimoz™
% basic	19.7–29.3 (24.5)	10.8–16.5 (13.7)	17.5–30.2 (23.9)	8.6–10.9 (9.8)	>20.3	12.9–17.7 (15.3)
% acidic	13.1–18.2 (15.7)	17.6–21.7 (19.7)	11.9–18.7 (15.3)	22.6–25.6 (24.1)	9.2–13.9 (11.6)	6.8–10.7 (8.8)
% afucosylated	7.5–13.3 (10.4)	6.7–10.8 (8.8)	1.6–2.3 (2.0)	2.0–3.6 (2.8)	0.5–0.9 (0.7)	2.4–3.2 (2.8)
% sialylated	0.1–0.3 (0.2)	0.5–1.2 (0.9)	0.0–0.6 (0.3)	2.1–3.5 (2.8)	<LOQ	0.3–0.5 (0.4)
% galactosylated	16.5–23.0 (19.8)	19.9–39.2 (29.6)	18.3–21.4 (19.9)	19.3–28.3 (23.8)	14.7–23.1 (37.8)	23.7–37.4 (30.6)
% high mannose	5.6–10.6 (8.1)	5.0–8.5 (6.8)	4.4–9.3 (6.9)	5.3–9.9 (7.6)	3.9–6.6 (5.3)	0.9–1.3 (1.1)
% C terminal lysine	n/a	n/a	5.7–9.6 (7.7)	1.3–3.1 (2.2)	13.3–18.7 (16.0)	3.1–6.0 (4.6)